Hong Kong to toughen regs

Sound familiar? Following several drug "incidents," Hong Kong is beefing up its drug regulatory arm. Although a nine-month investigation finds that the existing framework is "sound and should be retained," a report sent to the Legislative Council Panel on Health Services this week says "the coverage and depth of regulation needs to be strengthened," according to a government announcement.

The report includes 75 recommendations. Among the more familiar-sounding: strengthening the tracking system for drugs; surveillance of high-risk products and enhanced pharmacovigilance activities; and the development of guidelines on risk assessment and communication in response to drug incidents.

More fundamentally, the report recommends upgrading the current Hong Kong GMP standard to a higher international standard and requiring microbiological monitoring for non-sterile drugs during manufacture. Also recommended is licensing of repackagers and wholesalers, improving drug quality checks; and tougher penalties for those who violate the regulations.

- here's the announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.